CTOs on the Move

Amarillo Biosciences

www.amarbio.com

 
Amarillo Biosciences, Inc. is a Amarillo, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.amarbio.com
  • 800 SW 9th Ave
    Amarillo, TX USA 79101
  • Phone: 806.376.1741

Executives

Name Title Contact Details

Funding

Amarillo Biosciences raised $20M on 05/03/2021

Similar Companies

Vitality

Vitality is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Northstar RX

Northstar RX is a Memphis, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The Nature`s Bounty Corporation

The Nature`s Bounty Co. has a history of championing health and wellness tracing back 145 years. Putting science and the highest quality standards at the heart of our business, the brands of The Nature`s Bounty Co. are some of the most trusted in the world. Always motivated by our commitment to excellence, our vision for health and wellness has inspired leading brands such as Nature`s Bounty, Sundown Naturals, Solgar, Holland & Barrett, Osteo Bi-Flex, Ester-C, MET-Rx, Pure Protein, Balance, Body Fortress, Puritan`s Pride and Organic Dr., among others. As a leading global manufacturer, marketer, distributor and retailer of vitamins, nutritional supplements, sports & active nutrition and ethical beauty products, The Nature`s Bounty Co. is committed to supporting wellness in all its forms.

Vishay BLH

BLH provides precision load cells, weight and force measurement systems, strain gages, web tension transducers, and instrumentation

Gemini Therapeutics

Gemini Therapeutics is a precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases. Our therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world, we are developing a series of first-in-class therapeutics.